Internal Medicine, Endocrinology, Diabetes, & Metabolism · Overland Park, KS
NPI
1982645792
Since 2006
Specialty
Internal Medicine, Endocrinology, Diabetes, & Metabolism
Code 207RE0101X
Group practices
1
Medicare group memberships
Hospitals
3
Hospital affiliations
12541 Foster St Ste 240
Overland Park, KS, 66213
Phone (913) 317-3170
Groups this clinician bills Medicare through
Medicare paid, 2024
$122K
2,646 services
Medicare patients, 2024
594
Average age 75
Drug cost, 2024
$3.5M
8,316 prescriptions
Company payments, 2025
$36.97
From 1 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Jeffrey D Kallsen was code 99214 (office e&m - established), 744 times for 449 patients. In total Jeffrey D Kallsen billed 2,646 services in 21 codes, and Medicare paid $122K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2024-02-27.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99214 Office E&M - Established | Office | 744 | 449 | $83.02 | $62K |
| 83036 Blood Count | Office | 654 | 329 | $9.49 | $6,207 |
| 95251 Test - Miscellaneous | Office | 502 | 220 | $24.09 | $12K |
| 36415 Venipuncture Blood Collection | Office | 328 | 272 | $8.65 | $2,837 |
| 99215 Office E&M - Established | Office | 266 | 180 | $114.52 | $30K |
| 99213 Office E&M - Established | Office | 42 | 42 | $60.04 | $2,521 |
| 99204 Office E&M - New | Office | 30 | 30 | $111.14 | $3,334 |
| G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | Office | 21 | 21 | $8.07 | $169 |
| 99205 Office E&M - New | Office | 14 | 14 | $124.23 | $1,739 |
| 95249 Test - Miscellaneous | Office | 12 | 12 | $32.94 | $395 |
By year: 2022 $199K for 7,360 services; 2023 $146K for 4,276 services; 2024 $122K for 2,646 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 83036 Blood Count | 654 | 329 | $9.49 | $6,207 |
| 36415 Venipuncture Blood Collection | 328 | 272 | $8.65 | $2,837 |
Medicare prescription drug claims, 2024
In 2024, the drug Jeffrey D Kallsen prescribed most often to Medicare patients was Ozempic (Semaglutide), with 738 prescriptions and refills. In total Jeffrey D Kallsen wrote 8,316 Medicare prescriptions that cost $3.5M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Ozempic Semaglutide | 738 | 1,135 | 142 | $1.1M |
| Levothyroxine Sodium Generic | 697 | 1,966 | 203 | $7,683 |
| Jardiance Empagliflozin | 435 | 878 | 101 | $499K |
| Lantus Solostar Insulin Glargine,hum.Rec.Anlog | 404 | 928 | 114 | $56K |
| Metformin Hcl Er Metformin Hcl | 344 | 901 | 104 | $4,401 |
| Pioglitazone Hcl Generic | 315 | 836 | 83 | $2,912 |
| Humalog Kwikpen U-100 Insulin Lispro | 295 | 618 | 90 | $110K |
| Atorvastatin Calcium Generic | 274 | 761 | 86 | $2,934 |
| Novolog Flexpen Insulin Aspart | 255 | 521 | 93 | $98K |
| Metformin Hcl Generic | 242 | 679 | 71 | $2,031 |
| Rosuvastatin Calcium Generic | 241 | 656 | 71 | $2,655 |
| Synthroid Levothyroxine Sodium | 178 | 508 | 51 | $16K |
| Irbesartan Generic | 164 | 486 | 52 | $4,438 |
| Nano 2nd Gen Pen Needle Pen Needle, Diabetic | 164 | 430 | 67 | $26K |
| Tresiba Flextouch U-100 Insulin Degludec | 162 | 432 | 49 | $126K |
Brand drugs: 3,978 claims; generic drugs: 3,735 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Jeffrey D Kallsen $36.97 ($36.97 in general payments such as food, travel and fees) from 1 company. The largest payer was Medtronic, Inc. with $36.97.
| Company | Payments | Amount |
|---|---|---|
| Medtronic, Inc. MDT | 1 | $36.97 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.